Levodopa in the treatment of Parkinson’s disease-Reference-Cited by-同舟云学术

Levodopa in the treatment of Parkinson’s disease

Published:2006 Issue: Volume: Page:1-15
ISSN:
Container-title:Oxidative Stress and Neuroprotection
language:
Short-container-title:

Author:

Fahn S.

Publisher

Springer Vienna

Link

http://link.springer.com/content/pdf/10.1007/978-3-211-33328-0_1

Reference115 articles.

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P (2003) Prevalence and characteristics of dementia in Parkinson disease — An 8-year prospective study. Arch Neurol 60: 387–392

2. Aebert K (1967) Was leistet L-DOPA bei der Behandlung der Parkinson-Akinese? Deutsch Med Wschr 92: 483–487

3. Agid Y (1998) Levodopa: is toxicity a myth? Neurology 50: 858–863

4. Albin RL, Frey KA (2003) Initial agonist treatment of Parkinson disease: a critique. Neurology 60: 390–394

5. Barbeau A, Sourkes TL, Murphy GF (1962) Les catecholamines dans la maladie de Parkinson. In: de Ajuriaguerra J (eds) Symposium Sur les Monoamines et Systeme Nerveux Central. Georg & Cie, Geneve: pp 247–262

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Associations between gut microbiota characteristics and non‐motor symptoms following pharmacological and surgical treatments in Parkinson's disease patients;Neurogastroenterology & Motility;2024-06-14

2. A voltammetric method coupled with chemometrics for determination of a ternary antiparkinson mixture in its dosage form: greenness assessment;BMC Chemistry;2024-05-09

3. Toxic interactions between dopamine, α-synuclein, monoamine oxidase, and genes in mitochondria of Parkinson’s disease;Journal of Neural Transmission;2024-01-09

4. The role of dopamine in NLRP3 inflammasome inhibition: Implications for neurodegenerative diseases;Ageing Research Reviews;2023-06

5. Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease;Journal of Neural Transmission;2023-05-20